Reveals AChE inhibitory activity of xeniaphyllane-type diterpenoids from soft coral, suggesting neurotherapeutic prospects.
High Resolution Image Download MS PowerPoint Slide A combined bioassay- and 1 H NMR-guided isolation strategy led to the discovery of four new terpenoids, including three xeniaphyllane-type diterpenoids, sclerohumins P–R ( 1–3 ), and a norcaryophyllene-type, sclerophyllene A ( 4 ), from the soft coral Sclerophytum humesi . The structures and absolute configurations of these compounds were elucidated by comprehensive spectroscopic analysis, including NMR, HRESIMS, SOR, TDDFT-ECD, and DP4+ probability analysis. The stereogenic centers at C-15 in related xeniaphyllanes were proposed for the first time based on comparative SOR analysis. Compounds 1 and 2 possess a tricyclic 4/9-fused carbocyclic framework featuring an epoxide moiety, whereas compounds 3 and 4 exhibit related bicyclic scaffolds. A plausible biogenetic pathway originating from geranylgeranyl pyrophosphate (GGPP) was proposed to account for their structural diversity. Compounds 1 and 2 showed potent AChE inhibitory activity (IC 50 = 1.7 and 4.4 μM, respectively), while being inactive against BChE and noncytotoxic toward normal cell lines (HEK293 and Vero). Mechanistic studies combining enzyme kinetics and molecular docking revealed that 1 and 2 act as mixed-type AChE inhibitors, with K i values of 1.02 and 1.87 μM, respectively. These findings represent the first report of xeniaphyllane-type diterpenoids with potential for neurotherapeutic development.
No takes yet. Share an insight, caveat, or question.
Luu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: